FDA Approved Temodar
The U.S Food and Drug Administration's approval of Temodar as a treatment for people newly diagnosed with glioblastoma recognizes the importance of hope. These reports signify movement in the treatment of one of the most aggressive brain tumors.
(PRWEB) March 18, 2005 -- The U.S Food and Drug Administration’s approval of
Temodar as a treatment for people newly diagnosed with glioblastoma recognizes
the importance of hope. A study published by Roger Stupp, MD, for the European
Organization for Research and Treatment of Cancer (EORTC) in last week’s New
England Journal of Medicine found that adding Temodar to radiation therapy
increased survival rates to 26.5% at two years (from 10.4 % with radiation
alone). In an equally compelling report also published in the same journal,
studies at the University Hospital of Lausanne indicate the interaction between
this drug and a biologic marker called MGMT may provide important information
for researchers. These reports signify movement in the treatment of one of the
most aggressive brain tumors.
Glioblastoma multiforme is the most common
of the primary malignant brain tumors, and is also one of the most difficult
tumors to treat effectively. Each year, approximately 20% of all reported brain
tumors are glioblastoma. Generally found in people forty through sixty years
old, glioblastoma occurs slightly more often in males than females. This tumor
tends to be found in the cerebral hemispheres of the brain that control memory,
thinking abilities, personality, and movement.
The American Brain Tumor
Association offers information about glioblastoma multiforme and Temodar; about
other types of brain tumors and their treatments; about standard therapies as
well as research treatments; and about support options for brain tumor families
seeking help in living with the diagnosis of a brain tumor. Call us at
800-886-2282, or visit our web site at www.abta.org
Physicians available for
interviews.
This week’s headlines share our hope… the hope that new
knowledge brings to the quality of lives of brain tumor patients around the
globe.
Contact:
American Brain Tumor Association
2720 River
Rd.
Des Plaines, Il 60618
847-827-9910
www.abta.org
# # #
Source : http://www.prweb.com/releases/2005/3/prweb219054.htm